Tag Archives: Warren Woessner

USPTO Encourages Prosecution After Final – Sort of

Posted on April 4, 2012 by Warren Woessner

Although entry of any amendments after final rejection has always be discretionary with Examiners, for pretty much my entire career, I have had good luck continuing prosecution after final rejection – sometimes filing multiple Rule 116 amendments or making multiple … Continue reading →

Posted in USPTO Practice and Policy | Tagged , , , | 1 Comment

Mayo v. Prometheus – A European View

Posted on March 29, 2012 by Warren Woessner

A Guest Post from Paul Cole, European Patent Attorney, Lucas & Co; Professor of IP law, Bournemouth University. Is a claim to an assay patent-eligible when all its features are known save for how it should be interpreted? The interpretation … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , | 3 Comments

Legal Challenge To “ObamaCare” Threatens Generic Biologicals

Posted on March 29, 2012 by Warren Woessner

What should not be lost on pharma/biotech patent attorneys or their clients, amidst all the attention given to the Supreme Court’s review of the “Patient Protection and Affordable Health Care Act” – public law 111-48, is that it contains the … Continue reading →

Posted in Follow-On Biologics | Tagged , , , , | 1 Comment

Supreme Court Remands In Myriad Appeal

Posted on March 26, 2012 by Warren Woessner

Today, as predicted by many commentators, the Supreme Court set aside the ruling by the Fed. Cir. that claims to isolated DNA sequences that are the BRCA 1 or 2 gene, or fragments thereof, are patentable subject matter. The Supreme … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , , , | 1 Comment